S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
Free Webinar | October 11: How to Break Barriers
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
Rivian Checks Off Boxes, But Still Needs a Lot to Go Right
Live Updates: Russia-Ukraine War
A Potential Fintech Unicorn (Ad)
Too Soon: 3 Reasons to Wait on DocuSign Stock
OPEC+ makes big oil cut to boost prices; pump costs may rise
A Potential Fintech Unicorn (Ad)
3 Alzheimer Stocks to Buy as the Race for a Cure Heats Up
Hot Potato: Lamb Weston Stock Confirms a Top 
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
Free Webinar | October 11: How to Break Barriers
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
Rivian Checks Off Boxes, But Still Needs a Lot to Go Right
Live Updates: Russia-Ukraine War
A Potential Fintech Unicorn (Ad)
Too Soon: 3 Reasons to Wait on DocuSign Stock
OPEC+ makes big oil cut to boost prices; pump costs may rise
A Potential Fintech Unicorn (Ad)
3 Alzheimer Stocks to Buy as the Race for a Cure Heats Up
Hot Potato: Lamb Weston Stock Confirms a Top 
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
Free Webinar | October 11: How to Break Barriers
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
Rivian Checks Off Boxes, But Still Needs a Lot to Go Right
Live Updates: Russia-Ukraine War
A Potential Fintech Unicorn (Ad)
Too Soon: 3 Reasons to Wait on DocuSign Stock
OPEC+ makes big oil cut to boost prices; pump costs may rise
A Potential Fintech Unicorn (Ad)
3 Alzheimer Stocks to Buy as the Race for a Cure Heats Up
Hot Potato: Lamb Weston Stock Confirms a Top 
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
Free Webinar | October 11: How to Break Barriers
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
Rivian Checks Off Boxes, But Still Needs a Lot to Go Right
Live Updates: Russia-Ukraine War
A Potential Fintech Unicorn (Ad)
Too Soon: 3 Reasons to Wait on DocuSign Stock
OPEC+ makes big oil cut to boost prices; pump costs may rise
A Potential Fintech Unicorn (Ad)
3 Alzheimer Stocks to Buy as the Race for a Cure Heats Up
Hot Potato: Lamb Weston Stock Confirms a Top 
NASDAQ:OCUL

Ocular Therapeutix - OCUL Stock Forecast, Price & News

$4.38
-0.03 (-0.68%)
(As of 10/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.24
$4.45
50-Day Range
$4.09
$6.50
52-Week Range
$2.91
$12.50
Volume
679,755 shs
Average Volume
1.35 million shs
Market Capitalization
$337.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.50

Ocular Therapeutix MarketRank™ Forecast

Analyst Rating
Buy
3.25 Rating Score
Upside/​Downside
322.4% Upside
$18.50 Price Target
Short Interest
Healthy
3.78% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.01
Upright™ Environmental Score
News Sentiment
0.79mentions of Ocular Therapeutix in the last 14 days
Based on 9 Articles This Week
Insider Trading
Acquiring Shares
$684,352 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.87) to ($0.71) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.59 out of 5 stars

Medical Sector

118th out of 1,072 stocks

Pharmaceutical Preparations Industry

45th out of 534 stocks

OCUL stock logo

About Ocular Therapeutix (NASDAQ:OCUL) Stock

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Receive OCUL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ocular Therapeutix and its competitors with MarketBeat's FREE daily newsletter.

OCUL Stock News Headlines

Ocular Therapeutix (NASDAQ:OCUL) Downgraded by StockNews.com
Ocular (OCUL) Announces Positive Data on Wet AMD Candidate
Ocular Therapeutix Q2 2022 Earnings Preview
Ocular Therapeutix Tops Q1 EPS by 4c
See More Headlines
Receive OCUL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ocular Therapeutix and its competitors with MarketBeat's FREE daily newsletter.

OCUL Company Calendar

Last Earnings
8/08/2022
Today
10/06/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OCUL
Employees
228
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$18.50
High Stock Price Forecast
$29.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+322.4%
Consensus Rating
Buy
Rating Score (0-4)
3.25
Research Coverage
4 Analysts

Profitability

Net Income
$-6,550,000.00
Pretax Margin
-65.11%

Debt

Sales & Book Value

Annual Sales
$43.52 million
Book Value
$1.15 per share

Miscellaneous

Free Float
74,196,000
Market Cap
$337.13 million
Optionable
Optionable
Beta
1.48

Key Executives

  • Mr. Antony MattessichMr. Antony Mattessich (Age 55)
    Pres, CEO & Director
    Comp: $1.04M
  • Mr. Donald Notman Jr.
    Chief Financial Officer
  • Dr. Peter K. Jarrett Ph.D. (Age 65)
    Chief Scientific Officer
  • Mr. Philip C. Strassburger (Age 62)
    Gen. Counsel
  • Mr. William H. Ransone II
    VP of Global Sales & Marketing
  • Ms. Tracy Smith
    VP of HR
  • Mr. Scott Corning
    Sr. VP of Commercial
  • Mr. Christopher G. White (Age 60)
    Chief Bus. Officer
  • Dr. Rabia Gurses Ozden M.D. (Age 54)
    Chief Medical Officer
  • Dr. Karen-Leigh Edwards M.B.A.
    Ph.D., Sr. VP of Technical Operations













OCUL Stock - Frequently Asked Questions

Should I buy or sell Ocular Therapeutix stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last twelve months. There are currently 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OCUL shares.
View OCUL analyst ratings
or view top-rated stocks.

What is Ocular Therapeutix's stock price forecast for 2022?

4 brokerages have issued 1 year price objectives for Ocular Therapeutix's stock. Their OCUL share price forecasts range from $10.00 to $29.00. On average, they anticipate the company's stock price to reach $18.50 in the next twelve months. This suggests a possible upside of 322.4% from the stock's current price.
View analysts price targets for OCUL
or view top-rated stocks among Wall Street analysts.

How have OCUL shares performed in 2022?

Ocular Therapeutix's stock was trading at $6.97 on January 1st, 2022. Since then, OCUL shares have decreased by 37.2% and is now trading at $4.38.
View the best growth stocks for 2022 here
.

When is Ocular Therapeutix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our OCUL earnings forecast
.

How were Ocular Therapeutix's earnings last quarter?

Ocular Therapeutix, Inc. (NASDAQ:OCUL) announced its quarterly earnings data on Monday, August, 8th. The biopharmaceutical company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.23) by $0.05. The biopharmaceutical company earned $12.27 million during the quarter, compared to analysts' expectations of $13.81 million. Ocular Therapeutix had a negative net margin of 65.11% and a negative trailing twelve-month return on equity of 43.96%.

What other stocks do shareholders of Ocular Therapeutix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ocular Therapeutix investors own include Clearside Biomedical (CLSD), Northwest Biotherapeutics (NWBO), Novavax (NVAX), Dynavax Technologies (DVAX), Omeros (OMER), Gilead Sciences (GILD), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO) and SCYNEXIS (SCYX).

What is Ocular Therapeutix's stock symbol?

Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."

How do I buy shares of Ocular Therapeutix?

Shares of OCUL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ocular Therapeutix's stock price today?

One share of OCUL stock can currently be purchased for approximately $4.38.

How much money does Ocular Therapeutix make?

Ocular Therapeutix (NASDAQ:OCUL) has a market capitalization of $337.13 million and generates $43.52 million in revenue each year. The biopharmaceutical company earns $-6,550,000.00 in net income (profit) each year or ($0.93) on an earnings per share basis.

How many employees does Ocular Therapeutix have?

The company employs 228 workers across the globe.

How can I contact Ocular Therapeutix?

Ocular Therapeutix's mailing address is 15 CROSBY DRIVE, BEDFORD MA, 01730. The official website for the company is www.ocutx.com. The biopharmaceutical company can be reached via phone at (781) 357-4000, via email at chris.brinzey@westwicke.com, or via fax at 781-357-4001.

This page (NASDAQ:OCUL) was last updated on 10/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.